These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 12873289)

  • 1. Effect of the rapid-acting insulin analogue insulin aspart on quality of life and treatment satisfaction in patients with Type 1 diabetes.
    Bott U; Ebrahim S; Hirschberger S; Skovlund SE
    Diabet Med; 2003 Aug; 20(8):626-34. PubMed ID: 12873289
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Post-prandial administration of the insulin analogue insulin aspart in patients with Type 1 diabetes mellitus.
    Brunner GA; Hirschberger S; Sendlhofer G; Wutte A; Ellmerer M; Balent B; Schaupp L; Krejs GJ; Pieber TR
    Diabet Med; 2000 May; 17(5):371-5. PubMed ID: 10872536
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Parental preference of prandial insulin aspart compared with preprandial human insulin in a basal-bolus scheme with NPH insulin in a 12-wk crossover study of preschool children with type 1 diabetes.
    Danne T; Råstam J; Odendahl R; Näke A; Schimmel U; Szczepanski R; Moeller J; Deiss D
    Pediatr Diabetes; 2007 Oct; 8(5):278-85. PubMed ID: 17850471
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glycaemic control in type 1 diabetic patients using optimised insulin aspart or human insulin in a randomised multinational study.
    Tamás G; Marre M; Astorga R; Dedov I; Jacobsen J; Lindholm A;
    Diabetes Res Clin Pract; 2001 Nov; 54(2):105-14. PubMed ID: 11640994
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety comparison of rapid-acting insulin aspart and regular human insulin in the treatment of type 1 and type 2 diabetes mellitus: a systematic review.
    Rys P; Pankiewicz O; Łach K; Kwaskowski A; Skrzekowska-Baran I; Malecki MT
    Diabetes Metab; 2011 Jun; 37(3):190-200. PubMed ID: 21333580
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy, safety and lack of immunogenicity of insulin aspart compared with regular human insulin for women with gestational diabetes mellitus.
    Pettitt DJ; Ospina P; Howard C; Zisser H; Jovanovic L
    Diabet Med; 2007 Oct; 24(10):1129-35. PubMed ID: 17888133
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Maternal glycemic control and hypoglycemia in type 1 diabetic pregnancy: a randomized trial of insulin aspart versus human insulin in 322 pregnant women.
    Mathiesen ER; Kinsley B; Amiel SA; Heller S; McCance D; Duran S; Bellaire S; Raben A;
    Diabetes Care; 2007 Apr; 30(4):771-6. PubMed ID: 17392539
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Insulin aspart vs. human insulin in the management of long-term blood glucose control in Type 1 diabetes mellitus: a randomized controlled trial.
    Home PD; Lindholm A; Riis A;
    Diabet Med; 2000 Nov; 17(11):762-70. PubMed ID: 11131100
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Equal metabolic control but superior caregiver treatment satisfaction with insulin aspart in preschool children.
    Pańkowska E; Nazim J; Szalecki M; Urban M
    Diabetes Technol Ther; 2010 May; 12(5):413-8. PubMed ID: 20388052
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of insulin aspart, a fast-acting insulin analog, as the mealtime insulin in the management of patients with type 1 diabetes.
    Raskin P; Guthrie RA; Leiter L; Riis A; Jovanovic L
    Diabetes Care; 2000 May; 23(5):583-8. PubMed ID: 10834413
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune responses to insulin aspart and biphasic insulin aspart in people with type 1 and type 2 diabetes.
    Lindholm A; Jensen LB; Home PD; Raskin P; Boehm BO; Råstam J
    Diabetes Care; 2002 May; 25(5):876-82. PubMed ID: 11978684
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insulin aspart: a review of its use in the management of type 1 and 2 diabetes mellitus.
    Chapman TM; Noble S; Goa KL
    Drugs; 2002; 62(13):1945-81. PubMed ID: 12215068
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the pharmacokinetic and pharmacodynamic profiles of biphasic insulin aspart 50 and 30 in patients with type 2 diabetes mellitus: a single-center, randomized, double-blind, two-period, crossover trial in Japan.
    Hirao K; Maeda H; Urata S; Takisawa Y; Hirao S; Sasako T; Sasaki T
    Clin Ther; 2007 May; 29(5):927-934. PubMed ID: 17697911
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Similar glucose control with basal-bolus regimen of insulin detemir plus insulin aspart and thrice-daily biphasic insulin aspart 30 in insulin-naive patients with type 2 diabetes: Results of a 50-week randomized clinical trial of stepwise insulin intensification.
    Malek R; Ajili F; Assaad-Khalil SH; Shinde A; Chen JW; Van den Berg E
    Diabetes Metab; 2015 Jun; 41(3):223-30. PubMed ID: 25483023
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improved Postprandial Glycemic Control with Faster-Acting Insulin Aspart in Patients with Type 1 Diabetes Using Continuous Subcutaneous Insulin Infusion.
    Bode BW; Johnson JA; Hyveled L; Tamer SC; Demissie M
    Diabetes Technol Ther; 2017 Jan; 19(1):25-33. PubMed ID: 28055230
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fast-acting insulin aspart in Japanese patients with type 1 diabetes: Faster onset, higher early exposure and greater early glucose-lowering effect relative to insulin aspart.
    Shiramoto M; Nishida T; Hansen AK; Haahr H
    J Diabetes Investig; 2018 Mar; 9(2):303-310. PubMed ID: 28556616
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Insulin aspart improves meal time glycaemic control in patients with Type 2 diabetes: a randomized, stratified, double-blind and cross-over trial.
    Perriello G; Pampanelli S; Porcellati F; Avogaro A; Bosi E; Petrella G; Squatrito S; Furneri S; Marra G; Vitali L; Previti M; Cucinotta D
    Diabet Med; 2005 May; 22(5):606-11. PubMed ID: 15842516
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Postprandial glycemic control using insulin aspart with NPH in inadequately controlled diabetics].
    Gao Y; Pan CY; Zou DJ; Xu ZR; Liu XM; Guo XH
    Zhonghua Yi Xue Za Zhi; 2009 Jul; 89(28):1960-3. PubMed ID: 19950569
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of insulin aspart versus human soluble insulin in type 2 diabetes in four European countries: subgroup analyses from the PREDICTIVE study.
    Palmer JL; Goodall G; Nielsen S; Kotchie RW; Valentine WJ; Palmer AJ; Roze S
    Curr Med Res Opin; 2008 May; 24(5):1417-28. PubMed ID: 18400145
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Faster-acting insulin aspart provides faster onset and greater early exposure vs insulin aspart in children and adolescents with type 1 diabetes mellitus.
    Fath M; Danne T; Biester T; Erichsen L; Kordonouri O; Haahr H
    Pediatr Diabetes; 2017 Dec; 18(8):903-910. PubMed ID: 28165180
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.